India Infertility Gonadotropins Market
- 2026 年市場規模
- USD 273.0 Mn
- 2033 年預估規模
- USD 512.9 Mn
- 年複合成長率 CAGR
- 13.3%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
India Infertility Gonadotropins Market, By Type (Human Chorionic Gonadotropin (hCG), Follicle Stimulating Hormone (FSH), Menotropins (hMG), and Others), By Product Type (Branded and Generics), By Route of Administration (Intramuscular and Subcutaneous), By Application (Female Infertility and Male Infertility), By Type of Infertility (Primary Infertility and Secondary Infertility), By Age Group (1825, 2630, 3135, and 36 and Above), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Government Supply / Public Health Programs)
報告摘要
The India infertility gonadotropins market is estimated to be valued at USD 273.0 Mn in 2026 and is expected to reach USD 512.9 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 13.3% from 2026 to 2033. Infertility gonadotropins form an essential component segment of India’s fast-growing assisted reproductive technology (ART), owing to the increasing number of couples facing fertility issues in India. FSH, LH, and chorionic gonadotropin are examples of gonadotropins that help in regulating the functions of the ovaries, which is useful during fertility treatments, particularly IVF. Recombinant forms of such medications are generally recommended as they offer high purity.
There are several factors responsible for driving the growth rate of the market for infertility gonadotropins in India. These factors include increased awareness about reproductive issues, delayed marriages, infertility due to unhealthy lifestyles, and improved acceptance rates regarding fertility treatments. In addition, some other factors are disposable incomes, urbanization, proliferation of fertility centers in tier-I and tier-II cities, and medical advancements.
Market Dynamics
India infertility gonadotropins market is mainly driven by an increase in the number of infertility cases due to late parenthood, changes in lifestyle habits, and reproductive problems arising due to stress. Rising prevalence of assisted reproductive technology and reduced social taboos related to fertility have led to an increasing patient base. Also, the development of advanced technologies used in fertility treatments has played a key role in improving the success rates of IVF treatment.
The market faces some restraints, such as high cost of treatment, minimal or no reimbursement for the cost, high costs involved for medium and lower middle-class patients, adherence to standards, storage issues, among others. The opportunities in this market can arise through expanded availability of fertility clinics in semi-urban locations, increased medical tourism, fertility preservation, biologics and biosimilar drugs, and telemedicine services.
Key Features of the Study
• This report provides in-depth analysis of the India infertility gonadotropins market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the India infertility gonadotropins market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Merck KGaA, Ferring Pharmaceuticals, Organon & Co., IBSA Institut Biochimique SA, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, and Dr. Reddy's Laboratories Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The India infertility gonadotropins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India infertility gonadotropins market
Market Segmentation
• Type Insights (Revenue, USD Mn, 2021 - 2033)
o Human Chorionic Gonadotropin (hCG)
o Follicle Stimulating Hormone (FSH)
o Menotropins (hMG)
o Others
• Product Type Insights (Revenue, USD Mn, 2021 - 2033)
o Branded
o Generics
• Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
o Intramuscular
o Subcutaneous
• Application Insights (Revenue, USD Mn, 2021 - 2033)
o Female Infertility
o Male Infertility
• Type of Infertility Insights (Revenue, USD Mn, 2021 - 2033)
o Primary Infertility
o Secondary Infertility
• Age Group Insights (Revenue, USD Mn, 2021 - 2033)
o 18–25
o 26–30
o 31–35
o 36 and Above
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Government Supply / Public Health Programs
• Key Players Insights
o Merck KGaA
o Ferring Pharmaceuticals
o Organon & Co.
o IBSA Institut Biochimique SA
o Bharat Serums and Vaccines Limited
o Intas Pharmaceuticals Ltd.
o Sun Pharmaceutical Industries Ltd.
o Zydus Lifesciences Ltd.
o Lupin Limited
o Reddy's Laboratories Ltd.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
India Infertility Gonadotropins Market, By Type
India Infertility Gonadotropins Market, By Product Type
India Infertility Gonadotropins Market, By Route of Administration
India Infertility Gonadotropins Market, By Application
India Infertility Gonadotropins Market, By Type of Infertility
India Infertility Gonadotropins Market, By Age Group
India Infertility Gonadotropins Market, By Distribution Channel
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Key Developments
o Industry Trends
4. India Infertility Gonadotropins Market, By Type, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Human Chorionic Gonadotropin (hCG)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Follicle Stimulating Hormone (FSH)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Menotropins (hMG)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. India Infertility Gonadotropins Market, By Product Type, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Branded
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Generics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. India Infertility Gonadotropins Market, By Route of Administration, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Intramuscular
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. India Infertility Gonadotropins Market, By Application, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Female Infertility
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Male Infertility
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. India Infertility Gonadotropins Market, By Type of Infertility, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Primary Infertility
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Secondary Infertility
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. India Infertility Gonadotropins Market, By Age Group, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o 18-25
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o 26-30
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o 31-35
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o 36 and Above
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. India Infertility Gonadotropins Market, By Distribution Channel, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Government Supply / Public Health Programs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
11. Competitive Landscape
o Merck KGaA
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Ferring Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Organon & Co.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o IBSA Institut Biochimique SA
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Bharat Serums and Vaccines Limited
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Intas Pharmaceuticals Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Sun Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Zydus Lifesciences Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Lupin Limited
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Reddy's Laboratories Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
12. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
13. References and Research Methodology
o References
o Research Methodology
o About us
*Browse 32 market data tables and 28 figures on ‘Infertility Gonadotropins Market – India forecast to 2033
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們